E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
The heart has a reduced ability to supply the body with sufficient blood to perform optimally. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
In patients with heart failure who have an elevated concentration of procalcitonin (a marker of infection) which is not explained by clinical evidence of infection, can treatment for one week with azithromycin or with metronidazole reduce plasma concentrations of procalcitonin compared to a control group who receive no antibiotics. Procalcitonin is associated with a poor prognosis so understanding the mechanism for an elevated concentration in those without infection may provide a therapeutic target. |
|
E.2.2 | Secondary objectives of the trial |
Secondary endpoints are : Change in procalcitonin between baseline and two weeks change in procalcitonin between baseline and six weeks change in procalcitonin between one and two weeks change in procalcitonin between one and six weeks change in cardiovascular measurements at one, two and six week; time course of any cardiovascular changes and their relationship to changes in procalcitonin
In addition, we will evaluate the patients’ haemodynamic profiles in detail using painless, non-invasive technologies including measure of pulse wave velocity and characteristics (ENVERDIS), bio-impedance (NICAS), photo-plethysmography (NEXFIN) and Echocardiography. We will also measure a range of cardiovascular risk markers including(NT-proBNP, Galectin-3), inflammatory (hsCRP, PCT, acylation stimulatory protein, lipopolysaccharides and renal (NGAL) biomarkers in plasma, serum or urine. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Ability to give, legally valid, written informed consent • Clinical diagnosis of heart failure • NT-proBNP plasma concentration >400ng/L • Procalcitonin plasma concentration >50 pg/ml
|
|
E.4 | Principal exclusion criteria |
• Age <18 years • Inability to understand or read English. • Women of child bearing potential • Antibiotic use in the prior 6 weeks • Endocarditis • Any known cancer • Previous major adverse effect to azithromycin or metronidazole (eg:- allergy, severe diarrhoea, need for hospital treatment of adverse effect) • Unwilling to avoid alcohol for one week (requested in all arms of the study) • Surgery of any kind in previous 6 weeks (includes device implantation) • Heart transplant recipient • Recipient of a left ventricular assist device • Inability to follow instructions or comply with follow-up procedures • Porphyria (use of macrolides and metronidazole is contra indicated ) • Contra-indications to one week’s treatment with azithromycin, metronidazole (if not already listed in the exclusion criteria)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is change in procalcitonin from baseline to the evaluation at 7-days in patients who either receive an antibiotic compared to those that do not. We intend to compare
a) Both antibiotic arms grouped together to no antibiotic therapy b) Azithromycin to no therapy c) Metronidazole to no therapy
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
We measure procalcitonin concentrations at baseline (i.e. before the treatment is taken (or not, in the case of the control group)), after one week of treatment and then after two and six weeks of follow-up. |
|
E.5.2 | Secondary end point(s) |
• Change in procalcitonin between o baseline and two weeks o baseline and six weeks o one and two weeks o one and six weeks
• Changes in hsCRP, NT-proBNP, serum urea and creatinine, systolic blood pressure, systemic vascular resistance, augmentation index at one, two and six weeks. • Relationships between changes in procalcitonin and changes in hsCRP, NT-proBNP, serum urea and creatinine, acyaltion stimulatory protein, lipopolysaccaharides, systolic blood pressure, systemic vascular resistance, global augmentation index at one, two and six weeks.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Same as primary end-points |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Standard therapy for heart failure |
|
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will be complete 5 weeks after the 60th patient has completed one week of follow-up. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |